Research programme: CD26 antigen antagonists - Morphochem/Probiodrug

Drug Profile

Research programme: CD26 antigen antagonists - Morphochem/Probiodrug

Alternative Names: PD IV inhibitors - Morphochem/Probiodrug; Serine protease dipeptidyl peptidase IV inhibitors - Morphochem/Probiodrug

Latest Information Update: 22 Jul 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Morphochem AG; Probiodrug
  • Class Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Anxiety disorders; Major depressive disorder

Most Recent Events

  • 01 Dec 2005 Morphochem AG has been acquired by Biovertis AG
  • 18 Nov 2004 Preclinical trials in Anxiety disorders in Germany (PO)
  • 18 Nov 2004 Preclinical trials in Depression in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top